Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Interest & Investment Income (2019 - 2025)

Historic Interest & Investment Income for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $10.9 million.

  • Beam Therapeutics' Interest & Investment Income fell 1009.32% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.0 million, marking a year-over-year decrease of 1236.11%. This contributed to the annual value of $49.1 million for FY2024, which is 518.04% up from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Interest & Investment Income is $10.9 million, which was down 1009.32% from $12.3 million recorded in Q2 2025.
  • Beam Therapeutics' Interest & Investment Income's 5-year high stood at $14.2 million during Q2 2024, with a 5-year trough of -$52000.0 in Q2 2021.
  • For the 5-year period, Beam Therapeutics' Interest & Investment Income averaged around $7.6 million, with its median value being $10.0 million (2023).
  • In the last 5 years, Beam Therapeutics' Interest & Investment Income crashed by 12080.0% in 2021 and then soared by 5525555.56% in 2022.
  • Beam Therapeutics' Interest & Investment Income (Quarter) stood at $54000.0 in 2021, then surged by 13994.44% to $7.6 million in 2022, then skyrocketed by 58.51% to $12.1 million in 2023, then fell by 9.42% to $10.9 million in 2024, then fell by 0.23% to $10.9 million in 2025.
  • Its Interest & Investment Income was $10.9 million in Q3 2025, compared to $12.3 million in Q2 2025 and $9.9 million in Q1 2025.